News | Coronavirus (COVID-19) | May 20, 2020

Change Healthcare Launches COVID-19 Analytics Service

Actionable insight “beyond the diagnosis” enables health researchers to better understand COVID-19 progression, intervention effectiveness, and impacts on healthcare system

Actionable insight “beyond the diagnosis” enables health researchers to better understand COVID-19 progression, intervention effectiveness, and impacts on healthcare system

May 20, 2020 — Change Healthcare introduced Market Insights: COVID-19 Analytic Data Sets, an online COVID-19 research environment for qualified public and private healthcare organizations. The environment combines leading data science tools with comprehensive, timely, and statistically significant de-identified claims data, enabling researchers to move beyond test and diagnosis counts into real understanding of disease progression, intervention effectiveness, and impacts upon the healthcare system.

The remediation of COVID-19 has been hampered by limited data. Researchers need more than daily counts of diagnoses and tests to truly understand the disease. Given the complexity of COVID-19, analyses require comprehensive, timely, and statistically meaningful data. Most COVID-19 data are limited to static reports on the number of new cases, overall cases, deaths and geographical impact. While useful in preparing for resource allocation, it provides no insight into the disease progression and the efficacy of interventions––the type of data the medical community needs to take action.

Change Healthcare processes billions of U.S. medical and pharmacy claims every year, now including those related to COVID-19. Claims provide a more comprehensive view beyond the test or diagnosis, including other diagnoses, past care, and social determinants of health. Additionally, claims are coded by medical professionals without relying on self-reported patient data. Market Insights: COVID-19 Analytic Data Sets isolates claims into three unique data sets, all of which are de-identified and contractually permissioned: claims with explicit COVID-19 test and diagnosis codes; claims with codes identified in the February CDC interim billing guidelines; and claims with respiratory management diagnosis codes. These datasets are comprehensive, timely, and statistically meaningful for a variety of research initiatives.

“COVID researchers need more comprehensive and timely data in an environment where advanced data science can be responsibly performed,” said Tim Suther, senior vice president of Data Solutions at Change Healthcare. “These data sets enable robust analysis by the country’s leading medical data scientists to understand actual disease progression, the effectiveness of various interventions, and impacts to the healthcare system overall.”

Qualified researchers can apply to receive Market Insights: COVID-19 Analytic Data Sets from Change Healthcare, the COVID-19 Research Database, and AWS Data Exchange.

For more details, including subscription information on Market Insights: COVID-19 Analytic Data Sets, visit the Market Insights resource page.

Related Content

Kaplan-Meier curves for all-cause mortality in patients with versus without myocardial injury (Panel A) and in patients with versus without myocardial injury according to the presence or absence of major echocardiographic abnormalities (Panel B). *Includes wall motion abnormalities, global left ventricular dysfunction, diastolic dysfunction, right ventricular dysfunction and presence of pericardial effusion. Event rates are censored at 20 days from hospital admission. Images courtesy of Mount Sinai Health S

Kaplan-Meier curves for all-cause mortality in patients with versus without myocardial injury (Panel A) and in patients with versus without myocardial injury according to the presence or absence of major echocardiographic abnormalities (Panel B). *Includes wall motion abnormalities, global left ventricular dysfunction, diastolic dysfunction, right ventricular dysfunction and presence of pericardial effusion. Event rates are censored at 20 days from hospital admission. Images courtesy of Mount Sinai Health System

News | Ultrasound Imaging | October 28, 2020
October 28, 2020 — Card...
Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...
RaySearch Laboratories AB will demo its latest advances in oncology software at the American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting
News | Radiation Oncology | October 23, 2020
October 23, 2020 — RaySearch will present recent and upcoming enhancements, as well as new functionality, in...
A, Initial conventional axial CT image shows no noticeable lung damage (within red box) in right upper lobe. B, Electron density spectral CT image obtained at same time as image in A shows lesions (within red box) in right upper lobe. C, Follow-up conventional axial chest CT image obtained 5 days after images in A and B confirm presence of lesions (within red box) in right upper lobe.

A, Initial conventional axial CT image shows no noticeable lung damage (within red box) in right upper lobe. B, Electron density spectral CT image obtained at same time as image in A shows lesions (within red box) in right upper lobe. C, Follow-up conventional axial chest CT image obtained 5 days after images in A and B confirm presence of lesions (within red box) in right upper lobe. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | October 22, 2020
October 22, 2020 — According to an open-...
On Oct. 21, Seema Verma, administrator of the Centers for Medicare & Medicaid Services, tweeted that CMS will delay the Radiation Oncology Model’s launch from Jan. 1 to July 1 

Getty Images

News | ASTRO | October 22, 2020
October 22, 2020 — In response to the Oct.
Flowchart of patient inclusion and exclusion.

Figure 1. Flowchart of patient inclusion and exclusion.

News | Coronavirus (COVID-19) | October 20, 2020
October 20, 2020 — A new multi-institutional study published in the journal ...
Rensselaer, First-Imaging, and GE Global researchers develop a deep neural network to perform nearly as well as more complex dual-energy CT imaging technology
News | Computed Tomography (CT) | October 20, 2020
October 20, 2020 — Bioimaging technologies are the eyes that allow doctors to see inside the body in order to diagnos